Institute for Neurodegenerative Disorders Deploys OpenClinica EDC solution for Large Parkinson's Study
OpenClinica has been deployed as the electronic data capture and clinical data management system for a Parkinson's study that could involve up to 15,000 patients.
New Haven, CT (PRWEB) March 12, 2009
The Institutive for Neurodegenerative Disorders (IND) announces that has deployed the OpenClinica clinical data capture and management software for the Parkinson's Associated Risk Study (PARS).
PARS is a clinical study to develop a pre-motor Parkinson disease (PD) cohort using a combination of olfactory testing and dopamine transporter imaging to detect those at risk for PD. This ambitious project will recruit up to 15,000 study subjects from throughout the US who will participate in predictive testing. For more information about the PARS study, see http://www. parsinfosource. com/index. htm (http://www. parsinfosource. com/index. htm).
IND has selected OpenClinica to streamline clinical data collection and management for this clinical trial. Through the OpenClinica Enterprise program, the PARS study will receive a certified implementation of OpenClinica electronic data capture system (http://www. openclinica. org/section. php? sid=1), customization of certain features, training for users, and ongoing support for the popular open source eClinical software.
"We are excited about the progress of the PARS study and our collaboration with OpenClinica in this and other research studies sponsored by the Institute," said Dr. Danna Jennings, Clinical Research Director at IND. "In the PARS study, data management is a crucial component of success and OpenClinica has provided a flexible and versatile platform that will ensure the quality and consistency of the PARS data."
Through OpenClinica Enterprise, an organization conducting clinical research can obtain a spectrum of services to enhance their use of the OpenClinica software. OpenClinica Enterprise enables a research institution to maintain its independence from software vendors while obtaining full support for a modern, robust clinical research software technology.
About the Institute for Neurodegenerative Disorders
The Institute for Neurodegenerative Disorders (IND) is an independent not-for-profit research institute located in New Haven, Connecticut. The mission of IND is to develop improved treatments, diagnostic tools and educational programs for neurologic disorders such as Parkinson disease, Huntington disease and Alzheimer disease through clinical research.
IND specializes in clinical and neuroimaging research and is developing tools to diagnose neurologic disorders at the earliest possible stages of disease. IND also conducts large multi-center studies aimed at understanding medications that may influence the influence the disease's rate of progression. For more information see http://www. indd. org (http://www. indd. org).
About OpenClinica®
OpenClinica is open source web-based electronic data capture software for clinical research. It facilitates protocol configuration, design of case report forms, clinical data capture, and study/data management. OpenClinica supports HIPAA, GCP, and 21 CFR Part 11 guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. OpenClinica is available for download at http://www. openclinica. org (http://www. openclinica. org).
About Akaza Research®
Akaza Research, the leading provider of open source clinical trial software (http://www. openclinica. org), is headquartered in Cambridge, Massachusetts. Supported by the National Institutes of Health (NIH) and dozens of other leading research institutions, Akaza has developed and commercialized OpenClinica, the preeminent open source clinical trial data capture and management software platform. Akaza brings Open Source Software (OSS) into the mainstream of the clinical research enterprise by making robust, flexible, standards-based systems accessible for private and public research. Akaza Research provides OpenClinica support, training, and consulting services to its customers worldwide. See http://www. akazaresearch. com (http://www. akazaresearch. com).
###
